Tritonpoint Wealth LLC Has $15.83 Million Stock Holdings in Danaher Co. (NYSE:DHR)

Tritonpoint Wealth LLC cut its holdings in shares of Danaher Co. (NYSE:DHR - Free Report) by 4.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 77,073 shares of the conglomerate's stock after selling 3,322 shares during the quarter. Danaher comprises 1.5% of Tritonpoint Wealth LLC's investment portfolio, making the stock its 12th largest holding. Tritonpoint Wealth LLC's holdings in Danaher were worth $15,825,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Spinnaker Trust increased its position in shares of Danaher by 1.2% during the fourth quarter. Spinnaker Trust now owns 4,304 shares of the conglomerate's stock valued at $988,000 after purchasing an additional 50 shares during the period. Fortis Capital Advisors LLC increased its position in shares of Danaher by 1.3% during the fourth quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock valued at $914,000 after purchasing an additional 50 shares during the period. Fayez Sarofim & Co increased its position in shares of Danaher by 0.6% during the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock valued at $1,902,000 after purchasing an additional 50 shares during the period. Coastal Bridge Advisors LLC increased its position in shares of Danaher by 4.8% during the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock valued at $252,000 after purchasing an additional 50 shares during the period. Finally, Perennial Investment Advisors LLC increased its position in shares of Danaher by 2.2% during the fourth quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock valued at $538,000 after purchasing an additional 51 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on DHR shares. The Goldman Sachs Group lowered their price objective on Danaher from $260.00 to $240.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 23rd. Citigroup restated a "buy" rating on shares of Danaher in a research report on Monday, April 7th. Stifel Nicolaus upgraded Danaher from a "hold" rating to a "buy" rating and set a $260.00 price target on the stock in a research report on Friday, March 14th. Robert W. Baird lowered their price target on Danaher from $231.00 to $225.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 23rd. Finally, HSBC lowered their price target on Danaher from $270.00 to $240.00 in a research report on Friday, April 25th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat, Danaher presently has an average rating of "Moderate Buy" and a consensus price target of $248.17.

Danaher Trading Down 2.2%

Shares of DHR traded down $4.59 during trading hours on Friday, hitting $200.51. 3,391,410 shares of the stock traded hands, compared to its average volume of 3,490,806. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher Co. has a 1-year low of $171.00 and a 1-year high of $281.70. The firm has a market capitalization of $143.50 billion, a PE ratio of 37.98, a price-to-earnings-growth ratio of 2.66 and a beta of 0.77. The business has a fifty day moving average of $192.80 and a 200-day moving average of $211.00.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.82% and a net margin of 16.33%. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. Analysts expect that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.64%. Danaher's dividend payout ratio (DPR) is currently 24.85%.

Insiders Place Their Bets

In other news, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the sale, the executive vice president now owns 15,179 shares of the company's stock, valued at $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the sale, the chairman now directly owns 3,105,808 shares in the company, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.10% of the company's stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.